These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

818 related items for PubMed ID: 30390220

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ibrutinib in B lymphoid malignancies.
    Smith MR.
    Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
    [Abstract] [Full Text] [Related]

  • 7. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Gayko U, Fung M, Clow F, Sun S, Faust E, Price S, James D, Doyle M, Bari S, Zhuang SH.
    Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
    [Abstract] [Full Text] [Related]

  • 8. Ibrutinib.
    Charalambous A, Schwarzbich MA, Witzens-Harig M.
    Recent Results Cancer Res; 2018 Nov; 212():133-168. PubMed ID: 30069629
    [Abstract] [Full Text] [Related]

  • 9. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A, Brown JR.
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [Abstract] [Full Text] [Related]

  • 10. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
    Lucas F, Woyach JA.
    Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
    [Abstract] [Full Text] [Related]

  • 11. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
    Alinari L, Quinion C, Blum KA.
    Clin Pharmacol Ther; 2015 May; 97(5):469-77. PubMed ID: 25670208
    [Abstract] [Full Text] [Related]

  • 12. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
    Dostálová H, Kryštof V.
    Hematol Oncol; 2024 Jul; 42(4):e3294. PubMed ID: 38847437
    [Abstract] [Full Text] [Related]

  • 13. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A, Ravinet A, Bay JO, Tournilhac O, Guièze R, Lemal R.
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [Abstract] [Full Text] [Related]

  • 14. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V, Busygina K, Jamasbi J, Pekrul I, Spannagl M, Weber C, Lorenz R, Siess W.
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [Abstract] [Full Text] [Related]

  • 15. The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
    Hanna KS, Campbell M, Husak A, Sturm S.
    J Oncol Pharm Pract; 2020 Jul; 26(5):1190-1199. PubMed ID: 32279595
    [Abstract] [Full Text] [Related]

  • 16. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
    Hopper M, Gururaja T, Kinoshita T, Dean JP, Hill RJ, Mongan A.
    J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.
    Li S, Wu B, Zheng X, Wang C, Zhao J, Sun H, Sun X, Tang Z, Yuan H, Chen L, Ma X.
    Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709
    [Abstract] [Full Text] [Related]

  • 18. Ibrutinib and indolent B-cell lymphomas.
    Akinleye A, Furqan M, Adekunle O.
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):253-60. PubMed ID: 24445187
    [Abstract] [Full Text] [Related]

  • 19. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Bond DA, Alinari L, Maddocks K.
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
    [Abstract] [Full Text] [Related]

  • 20. Acalabrutinib for adults with mantle cell lymphoma.
    Jurczak W, Długosz-Danecka M, Wang M.
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):179-187. PubMed ID: 30638402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.